SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

Adults With Obesity More Likely to Ration Drugs to Save Money. Adults with obesity are more likely to ration their ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

Both drugs were also associated with a significantly reduced risk ... "Our study suggests that besides obesity and diabetes, ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

The current pain caused by the high cost of the GLP-1 agonist anti-obesity drugs will pass. Prachi Patkee and other analysts ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...